

FORM-PTO-1390
(Rev. 12-29-99)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

012627-024

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5)

09/914770INTERNATIONAL APPLICATION NO.
PCT/DE00/00693INTERNATIONAL FILING DATE
1 March 2000PRIORITY DATE CLAIMED
3 March 1999

TITLE OF INVENTION

COPPER AGONIST THAT BINDS ON THE COPPER BINDING SITE OF APP AND/OR EXERTS AN INHIBITING EFFECT ON THE RELEASE OF AMYLOID A β PEPTIDE

APPLICANT(S) FOR DO/EO/US

Colin L. MASTERS

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and the PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.

☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☐ Other items or information:

U.S. APPLICATION NO. (If known, see 37 CFR 1.101)

09/914770

INTERNATIONAL APPLICATION NO.
PCT/DE00/00693ATTORNEY'S DOCKET NUMBER
012627-02417. ☒ The following fees are submitted:

CALCULATIONS

PTO USE ONLY

Basic National Fee (37 CFR 1.492(a)(1)-(5)):

Neither international preliminary examination fee (37 CFR 1.482)
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO
and International Search Report not prepared by the EPO or JPO \$1,000.00 (960)

International preliminary examination fee (37 CFR 1.482) not paid to
USPTO but International Search Report prepared by the EPO or JPO \$860.00 (970)

International preliminary examination fee (37 CFR 1.482) not paid to USPTO
but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00 (958)

International preliminary examination fee paid to USPTO (37 CFR 1.482)
but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00 (956)

International preliminary examination fee paid to USPTO (37 CFR 1.482)
and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 (962)

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$ 860.00

Surcharge of \$130.00 (154) for furnishing the oath or declaration later than
months from the earliest claimed priority date (37 CFR 1.492(e)).

20 ☐ 30 ☐

Claims	Number Filed	Number Extra	Rate
Total Claims	9 -20 =	0	X\$18.00 (966)
Independent Claims	1 -3 =	0	X\$80.00 (964)

Multiple dependent claim(s) (if applicable)

+ \$270.00 (968)

TOTAL OF ABOVE CALCULATIONS =

\$ 860.00

Reduction for 1/2 for filing by small entity, if applicable (see below).

SUBTOTAL =

\$ 860.00

Processing fee of \$130.00 (156) for furnishing the English translation later than
months from the earliest claimed priority date (37 CFR 1.492(f)).

20 ☐ 30 ☐

+

TOTAL NATIONAL FEE =

\$ 860.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by
an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 (581) per property +

TOTAL FEES ENCLOSED =

\$ 860.00

Amount to be:
refunded \$

charged \$

a. ☐ Small entity status is hereby claimed.b. ☒ A check in the amount of \$ 860.00 to cover the above fees is enclosed.c. ☐ Please charge my Deposit Account No. 02-4800 in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed.d. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-4800. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Teresa Stanek Rea
BURNS, DOANE, SWECKER & MATHIS, L.L.P.
P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

SIGNATURE

Teresa Stanek Rea
NAME

30,427

REGISTRATION NUMBER

Patent
Attorney's Docket No. 012627-024

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Colin L. MASTERS) Group Art Unit: Unassigned
Application No.: Unassigned) Examiner: Unassigned
(Corresponding to PCT/DE00/00693))
International Filing Date: 1 March 2000)
For: COPPER AGONIST THAT BINDS)
ON THE COPPER BINDING SITE)
OF APP AND/OR EXERTS AN)
INHIBITING EFFECT ON THE)
RELEASE OF AMYLOID A β)
PEPTIDE)

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination, please amend the above-captioned application as follows:

IN THE CLAIMS:

Kindly replace claims 1-5 as follows.

1. (Amended) A method for the prevention or treatment of Alzheimer's disease comprising using a copper agonist which binds to the copper binding site of the amyloid precursor protein (APP) and/or reduces or prevents the release of the amyloid A β peptide.

2. (Amended) The method according to claim 1, wherein the copper agonists are divalent metal ions, oligopeptides, oligonucleotides, oligosaccharides, nucleotide analogs, chemical substance libraries or low molecular natural substances from microorganisms or plants.

3. (Amended) A method of identifying a copper agonist which binds to the copper binding site of APP and/or exerts an inhibitory effect on the release of the amyloid A β peptide, comprising the steps of:

- (a) contacting APP or a fragment thereof carrying the copper binding site with various concentrations of a compound which potentially has the above effect, and
- (b) detecting a decrease of the A β protein in mammals expressing the amyloid A β peptide.

4. (Amended) The method according to claim 3, wherein the decrease of the A β peptide is detected by means of ELISA or immunoprecipitation from cell culture systems.

5. (Amended) The method of identifying a copper agonist which binds to the copper binding site or APP and/or exerts an inhibitory effect on the release of the amyloid A β peptide comprising the steps of:

(a) contacting of APP or a fragment thereof carrying the copper binding site with a dissolved or immobilized substance library or with low molecular substances from microorganisms and/or plants,

(b) when a dissolved substance library or liquid low molecular substances are used immunoprecipitation of the competitive or non-competitive copper binding site/ligand complex from the solution with antibodies specific to APP or the fragment thereof or, when an immobilized substance library is used, release of the ligand from the copper binding site/ligand complex by the addition of copper salts,

(c) identification of the ligand, and

(d) selection of ligands which after binding to the copper binding site of APP exert an inhibitory effect on the release of the amyloid A β peptide, wherein step (d) can optionally precede step (c).

REMARKS

Entry of the foregoing amendment(s) is respectfully requested.

The claims have been amended to eliminate multiple dependency and to place them in better condition for U.S. patent practice.

Should the Examiner have any questions concerning the subject application, a telephone call to the undersigned would be appreciated.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 

Teresa Stanek Rea
Registration No. 30,427

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: September 4, 2001

Attachment to Preliminary Amendment dated September 4, 2001

Mark-up of Claims 1-5

1. (Amended) [Use of the] A method for the prevention or treatment of Alzheimer's disease comprising using a copper agonist which [is characterized in that it binds to the copper binding site of the amyloid precursor protein (APP) and/or reduces or prevents the release of the amyloid A β peptide [for the prevention or treatment of Alzheimer's disease].
2. (Amended) [Use] The method according to claim 1, wherein the copper agonists are divalent metal ions, oligopeptides, oligonucleotides, oligosaccharides, nucleotide analogs, chemical substance libraries or low molecular natural substances from microorganisms or plants.
3. (Amended) A method of identifying a copper agonist which binds to the copper binding site of APP and/or exerts an inhibitory effect on the release of the amyloid A β peptide, [which is characterized by] comprising the steps of:
 - (a) contacting APP or a fragment thereof carrying the copper binding site with various concentrations of a compound which potentially has the above effect, and
 - (b) detecting a decrease of the A β protein in mammals expressing the amyloid A β peptide.

Attachment to Preliminary Amendment dated September 4, 2001

Mark-up of Claims 1-5

4. (Amended) The method according to claim [5] 3, wherein the decrease of the A β peptide is detected by means of ELISA or immunoprecipitation from cell culture systems.

5. (Amended) The method of identifying a copper agonist which binds to the copper binding site or APP and/or exerts an inhibitory effect on the release of the amyloid A β peptide [which is characterized by] comprising the steps of:

(a) contacting of APP or a fragment thereof carrying the copper binding site with a dissolved or immobilized substance library or with low molecular substances from microorganisms and/or plants,

(b) when a dissolved substance library or liquid low molecular substances are used immunoprecipitation of the competitive or non-competitive copper binding site/ligand complex from the solution with antibodies specific to APP or the fragment thereof or, when an immobilized substance library is used, release of the ligand from the copper binding site/ligand complex by the addition of copper salts,

(c) identification of the ligand, and

(d) selection of ligands which after binding to the copper binding site of APP exert an inhibitory effect on the release of the amyloid A β peptide, wherein step (d) can optionally precede step (c).

09/914770

513 Rec'd PCT/PTO 04 SEP 2001

B 1824

6/ppts

Copper Agonist That Binds on the Copper Binding Site of APP
and/or Exerts an Inhibiting Effect on the Release of Amyloid
AB Peptide

The present invention relates to copper agonists which bind to the copper binding site of the amyloid precursor protein (APP) and/or exert an inhibitory effect on the release of the amyloid AB peptide which is involved in the development of Alzheimer's disease. The present invention also relates to medicaments containing these copper agonists for preventing and/or treating Alzheimer's disease. Finally, this invention concerns methods of identifying copper agonists having the effect desired for the purposes of the invention.

The β amyloid peptide (BA4, AB), the basic component of senile plaque and the cerebrovascular amyloid of Alzheimer's disease form by successive proteolytic cleavages with β -secretase and γ -secretase from the larger integral membrane amyloid precursor protein (APP) whose main isoforms contain 695 (APP695), 751 (APP751) or 770 (APP770) amino acids (Hardy, J., Trends Neurosci 20, pp. 154-159 (1997)). The APP processing within the AB domain by α -secretase prevents amyloid formation and leads to the release of the p3 peptide which contains the AB residues 17-40/42 (figure 1). The cleavage of APP with α -secretase or β -secretase produces soluble APP fragments (sAPP α and sAPP β) which represent the APP ectodomains supplied to the extracellular space.

Although the physiological role of APP is not known, APP shares some characteristics with cell adhesion molecules and

with molecules involved in wound healing. This comprises the binding sites of APP for heparin sulfate, collagen, laminin, proteases, lectins and metal ions, for example.

In the former experiments of treating Alzheimer's disease, the formation of the amyloid A β peptide was blocked by administering compounds blocking the hitherto unidentified β -secretase or γ -secretase (Hooper et al., Biochem. J. 321, pp. 265-279 (1997)). However, the inhibition of these proteases leads to undesired side effects, since these proteases are involved in the processing of different transmembrane proteins. The treatment of Alzheimer's disease and other forms of dementia has focused thus far on the improvement of the metabolic processes in the brain and the substitution of certain deficitary neurotransmitters or on the inhibition of the inflammatory processes accompanying this disease. However, these medicaments do not make a distinction between the different forms of dementia but aim at the secondary symptoms which can be observed in all dementias.

It is thus the technical problem of the present invention to provide products which are of use for preventing or treating Alzheimer's disease.

This technical problem has been solved by providing the embodiments characterized in the claims.

It has been found that APP interacts specifically with Zn(II) and Cu(II) at two defined locations. The binding of Cu(II) leads to an oxidation of two cysteines of APP, which results in the formation of an additional cystine. One of the two electrons produced in this way reduces the bound

copper(II) to form copper(I). However, the fate of the other electron has not been elucidated thus far.

It has now turned out that the addition of copper(II) effects in mammalian cells an increase in the release of the APP products of the α -secretory metabolic pathway (sAPP α and p3) and a decrease in the release of the products of the β -secretory metabolic pathway (p3.5 and the A β involved in Alzheimer's disease). Alzheimer's disease can thus be prevented or treated effectively and specifically by administering compounds which act as copper agonists, i.e. which can bind to the copper binding site of APP and/or imitate its physiological effect, i.e. can reduce or prevent the formation of the amyloid A β peptide. Since the copper binding by APP also leads to the production of very toxic Cu(I) ions, these molecules with an agonistic effect comprise the additional characteristic of preventing the cells from damage by the Cu(II) binding of APP and are thus able to prevent the formation of reactive forms of oxygen produced by copper and hydrogen peroxide.

Thus, an embodiment of the present invention relates to a copper agonist which is characterized in that it binds to the copper binding site of the amyloid precursor protein (APP) and/or reduces or prevents the release of the amyloid A β peptide.

The term "copper agonist" used herein concerns any substance, e.g. an inorganic or organic compound, which can bind to the copper binding site of APP and/or can reduce or prevent the release of the amyloid A β peptide. Preferred copper agonists are the divalent metal ions which may compete with copper for the binding site at the APP molecule at physiologically high concentrations, e.g. 20-200 mM

Mg(II), preferably 100 mM Mg(II), 20-200 mM Ca(II), preferably 100 mM Ca(II); 0.05-20 mM Zn(II), preferably 100 μ M Zn(II), etc. Further preferred copper agonists are oligopeptides, oligonucleotides, oligosaccharides or nucleotide analogs which imitate copper mainly via their three-dimensional structure and bind to the copper binding site according to the key-and-lock principle. In a preferred embodiment, the oligopeptides may also contain a sequence corresponding to the copper binding site and thus occupy it. Further preferred copper agonists are obtained from purchasable chemical substance libraries or are new chemical compounds (combined chemistry) or low molecular natural substances isolated from microorganisms or plants. These compounds also act via their three-dimensional structure which imitate the characteristics and size of copper without having its negative properties.

The effect as copper agonist is thus based preferably on the fact that the substance binds specifically and with an affinity higher than that of copper ions to the Cu binding site of APP or binds specifically to the sequence region of APP, which is responsible for copper binding and prevents (sterically) a further copper binding at that place or drives the copper ions from that place. Copper agonists are competitive (for the copper binding site) and non-competitive binding ligands which can imitate the physiological effect of copper. Copper agonists within the meaning of the present invention are also those substances which do not bind to the copper binding site but stabilize e.g. the conformation of APP which is characteristic of the copper APP complex, i.e. they can imitate the physiological effect of copper at other binding sites (beyond the direct copper binding site).

The term "reduces or prevents the release of the amyloid A β peptide" used herein relates to an effect of the copper agonist which can be referred to as sufficient to obtain a preventive or therapeutic effect as regards Alzheimer's disease.

A person skilled in the art is capable of identifying and producing substances having the above described effect as copper agonists by means of common methods used in the art. In the case of non-natural agonists (e.g. small organo-chemical synthesized substances available as what is called libraries), oligonucleotides, oligopeptides and nucleotide analogs, the synthesis is made according to common methods sufficiently known to the person skilled in the art. The identification of the substances as possible agonists can be made via affinity chromatography, e.g. using the "BIAcore technique". In this case, the above-mentioned compounds are tested for binding to APP, in particular to the domain of APP which comprises the copper binding site. Thereafter, the identified ligands are tested for an effect on the APP processing in the cell culture system, e.g. by means of competition assays with suitable antibodies. Moreover, the person skilled in the art can also test by means of common methods, e.g. in analogy to the methods described in Examples 4 and 5, whether the identified agonists can be tolerated by the patient and optionally prepare a dose-effect curve. The method according to the invention for identifying a copper agonist binding to the copper binding site of APP and/or exerting an inhibitory effect on the release of the amyloid A β peptide is therefore characterized by the following steps:

- (a) contacting APP or a fragment thereof carrying the copper binding site with various concentrations of a compound which potentially has the above effect,
- (b) detecting a decrease of the A β protein.

In a preferred embodiment, the method is characterized by the following steps:

- (a) contacting of APP or a fragment thereof carrying the copper binding site with a dissolved or immobilized substance library or with low molecular substances from microorganisms and/or plants,
- (b) when a dissolved substance library or liquid low molecular substances are used, immunoprecipitation of the copper binding site/ligand complex from the solution with antibodies specific to APP or the fragment thereof or, when an immobilized substance library is used, release of the ligand from the copper binding site/ligand complex by the addition of copper salts,
- (c) identification of the ligand, and
- (d) selection of ligands which by the competitive or non-competitive binding to the copper binding site of APP or to other sites of APP exert an inhibitory effect on the release of the amyloid A β peptide, wherein step (d) can optionally precede step (c).

A "ligand" according to the invention is understood to mean every substance which binds to the copper binding site or other sites of APP in the course of the above process.

The above mentioned antibodies are e.g. monoclonal or polyclonal antisera recognizing APP and suitable for immunoprecipitation. They can be purchased, e.g. from the companies of Boehringer Mannheim, Dianova or Sigma. Further suitable antibodies which can be used for detecting APP, APP complexes and A β 40 (isoform of A β having 40 amino acids, see figure 1) or A β 42 (isoform of A β having 42 amino acids, see figure 1) are described in Ida et al., J. Biol. Chem. 271, pp. 22908-22914 (1996) and Weidemann et al., Cell 57, pp. 155-162 (1989).

Collections of organo-chemical compounds which formed around lead substances due to random synthesis are used as substance libraries. These libraries can be purchased (e.g. from Morphosys, Munich; Analytikon, Berlin) or can be produced cooperatively by chemical laboratories (e.g. new chemical compounds by combined chemistry). Low molecular substances from microorganisms and plants can be isolated using the BIAcore technique.

Contacting is effected either in solution or with immobilized APP or with fragments of APP. The complexes formed are precipitated from the solution using antibodies and then detected using fluorescence, radioactivity or analytical methods, such as mass spectroscopy, gas chromatography, etc.

A suitable APP fragment is determined by initially testing the binding of the test substances to the entire APP and subsequently testing more and more shorter fragments which have the same binding characteristics as the full-length molecule.

Another possibility of carrying out step b) is by means of affinity chromatography, e.g. BIAcore, i.e. either APP molecules or its ligands are immobilized on a carrier surface. Thereafter, the corresponding molecule is injected onto this surface and when a binding has taken place copper salts are injected to resolve the binding again. This process can be pursued directly by the biosensor technique.

In a preferred embodiment of the identification method according to the invention, step (d) comprises the incubation of mammalian cells transfected stably with human APP695 with the ligands obtained from steps (a) to (c) and the determination of the production of the amyloid A β peptide with polyclonal or monoclonal antibodies. In this case, immunoprecipitation with subsequent SDS gel electrophoresis, ELISA and immunoprecipitation Western blots are in consideration as assays.

As an alternative, it is possible to proceed such that in step (d) the ligand obtained from steps (a) to (c) is administered to transgenic mice expressing the human amyloid A β peptide. Thereafter, a sample is collected from the CNS or the blood of the caudal vein and the production of the amyloid A β peptide with polyclonal or monoclonal antibodies is determined (e.g. companies of Dianova, Boehringer Mannheim, Sigma and own antibodies [Ida et al., J. Biol. Chem., 271, pp. 22908-22914, 1996]). This alternative method represents an *in vivo* test of the identified ligands. The procedure (including the methods used) is here very similar to the above described cell culture experiment. In place of detecting the APP fragments formed in the cell culture supernatant or intracellularly, in mice these fragments are detected in the serum. The detection methods correspond to those of the cell culture experiment.

The present invention also relates to medicaments containing the copper agonists according to the invention. These medicaments optionally contain in addition a pharmaceutically acceptable carrier. Suitable carriers and the formulation of such medicaments are known to the person skilled in the art. Suitable carriers are e.g. phosphate-buffered common salt solutions, water, emulsions, e.g. oil/water emulsions, wetting agents, sterile solutions, etc. The medicaments can be administered orally or parenterally. The methods for the parenteral administration comprise the topical, intra-arterial, intramuscular, subcutaneous, intramedullary, intrathecal, intraventricular, intravenous, intraperitoneal or intranasal administration. A suitable dosage is determined by the attending physician and depends on various factors, e.g. on the age, sex and/or weight of the patient, the stage of the disease, the kind of administration, etc.

Thus, the present invention also relates to the use of the above described copper agonists for the production of a medicament for preventing or treating Alzheimer's disease.

The invention is described in more detail by means of the figures according to which:

Figure 1 shows the processing of the amyloid precursor protein (APP770) into A β , p3.5 and p3.

One-letter code; the white letters designate the amino acid sequence of A β 1-40/42. The approximate position of the epitopes for the antibodies is indicated below the sequence with black bar.

Figure 2 shows the immunoprecipitation of c-myc-tagged APP695

Immunoprecipitation was made with polyclonal c-myc antibodies 18/47 from the lysate (myc-APP695) and the conditioned medium (myc-sAPP695) of the wild type (a, CHO-K1) and from copper-resistant CHO cells (b, CHO-CUR3). The precipitated samples were immunoblotted with the monoclonal APP antibody 22C11 after being transferred to a nitrocellulose membrane. Control: medium ("mock/s") and lysate ("mock/c") or "mock"-transfected cells.

Figure 3 shows the immunoprecipitation of Holo-APP695 from lysate (a), soluble APP695 (b) and A β and p3 from medium (d) of metabolically labeled CUR3 cells with anti-APP (22734/6; polyclonal serum from rabbits which was obtained by immunization with APP produced in bacteria, see figure 1) or anti-A β (730; polyclonal serum from rabbits which was obtained by immunization with synthetically produced A β 40 peptide) after 4-hour incubation in the presence of the copper chelating agents bathocuproin (BC) and D penicillamine (PEN) in common medium (CM; containing basal medium-copper) or in medium which contained the indicated copper concentrations

The appearance of sAPP695 as a doublet (b) at higher copper concentrations is based on its different sialic acid content. A fragment (d) running somewhat above the A β band occurs with low copper concentrations and is presumably produced by cleavage with δ -secretase and γ -secretase (see also figure 1). The relative amounts of cAPP (open triangles), sAPP (open squares) and entire secreted protein (black squares), which were measured in this experiment, were quantified as percentage of radioactivity, obtained with basal medium copper concentrate in c); A β (open squares), p3 (open triangles) and sAPP (black squares; the

data originating from the same experiment as in (c) are shown for better comparison) in (e). The data correspond to the average values from three independent experiments. "0" μM and "1" μM copper in (e) refer to incubation conditions for removal of copper (PEN/BC) and copper in the basal medium (CM; 0.8 μM).

Figure 4 shows the immunoprecipitation of Holo-APP695 from lysate (a), soluble APP695 (b) and A β and p3 from medium (d) of metabolically labeled K1 cells with anti-APP (22734/6) or anti-A β (730) after 4-hour incubation in the presence of the copper chelating agents bathocuproin (BC) and D penicillamine (PEN) in common medium (CM; containing basal medium-copper) or in medium which contained the indicated copper concentrations; quantified as in figure 3.

The endogenous level of sAPP751/770 is higher in K1 cells than in CUR3 cells (see figure 2) and is also influenced by the copper concentration and was thus quantified. The data are average values from two independent experiments. The relative amounts of cAPP (open circles), sAPP695 (open squares), sAPP751/770 (open triangles) and an entire secreted protein (black squares), which are measured in this experiment, are quantified in c). A β (open squares), p3 (open triangles) and sAPP695 (black squares; the data of the same experiment shown in c) in (e). "0" μM and "1" μM copper in (e) refer to incubation conditions for the removal of copper (PEN/BC) and copper in basal medium (CM; 0.8 μM). A fragment (d) somewhat running above the A β band occurs with low copper concentrations and is presumably produced by cleavage with δ -secretase and γ -secretase (see also figure 1).

Figure 5 shows the quantification of the relative levels of sAPP695, p3 and A β which were immunoprecipitated from conditioned medium of CHO-K1 cells (a) and CHO-CUR3 cells (b)

The increase in sAPP695 (black squares) achieved a maximum at 10 μ M Cu(II) (a) in K1 cells and at 50 μ M Cu(II) (b) in CUR3 cells; this was followed by a decrease. The change in the sAPP level (open triangles) occurred later as compared to the changes with the p3 protein which reached the maximum level with somewhat lower Cu(II) dosages, which is most likely due to a half life longer as compared to sAPP. In contrast thereto, the A β levels (black squares) increased drastically in both cell lines with Cu(II) concentrations below the basal level. The first data point was determined with the basal copper concentration (0.8 μ M Cu(II)).

The below examples illustrate the invention.

Example 1: General methods

Cells lines and transfections

CHO cells were transfected with a c-myc-tagged APP695 vector (Peraus et al., J. Neurosci 17, page 7714-7724 (1997)) or with the expression vector (pcDNA3) by means of a highly efficient calcium phosphate transfection (Chen et al., Biotechniques 6, pages 632-638 (1988)). The pSP65 (Invitrogen company) N-tag-APP 695 DNA was cloned into the vector pcDNA3 (Invitrogen/ITC Biotechnology, Heidelberg) using the SmaI or EcoRV cloning sites. The transfection efficiency was checked by means of immunoprecipitation of APP with polyclonal rabbit-anti-c-myc antibody (18/47; produced against the amino acid sequence EQKLISEEDL of the c-myc sequence; from Eurogentec, Seraing, Belgium) and immunoblots using the monoclonal mouse antibody 22C11 (Boehringer Mannheim) in the

"ECL" detection system (Amersham, Braunschweig). The parental CHO-K1 cells and the copper-resistant cell variant CUR3 were cultured at 37°C in "Eagles" medium (BME), to which 2 mM L-glutamine, 0.1 mM proline, 20 mM HEPES and 10 % fetal calf serum (Boehringer Ingelheim) were added. The basic copper concentration was 0.8 µM. CUR3 cells were cultured in a medium with 200 µM of copper added.

Metabolic Labeling and Immunoprecipitation

Stably transfected CHO cells of a culture dish (60 mm) were treated for 4 hours with 2 ml essential minimum medium (MEM) which contained no methionine (Sigma company, Munich) and was supplemented with 220 µCi [³⁵S]methionine (Amersham company, Braunschweig) and 5 % N₂. The conditioned medium (CM) and the cells were collected and immunoprecipitated. The protein concentrations were determined beforehand by means of a "BioRad" protein assay (Bradford et al., Anal. Biochem. 72, pages 248-254 (1976)) or the radioactively labeled proteins were precipitated with 10 % trichloroacetic acid (TCA) and the incorporated [³⁵S]methionine was measured (Beckman LS 6000IC). The cells were lysed in extraction buffer which contained 50 mM Tris-CH₃ (pH value 7.5), 150 mM NaCl, 2 mM EDTA, 2 % triton X-100, 2 % NP40, 10 µg/ml aprotinin and 10 µg/ml leupeptin. For removing cell debris, the lysate and the medium were centrifuged for 10 minutes at 13,000 x g and the medium was adjusted to 25 mM Tris-CH₃ (pH value 8.5), 1 mM PMSF, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 0.5 % triton X-100 and 0.5 % NP40. The solubilized proteins were diluted in 100 mM Tris-HCl (pH value 7.5), 300 mM NaCl and 4 mM EDTA at a concentration of 1:2. The supernatants were incubated overnight at 4°C with APP antibodies with end-over-end rotation in an overhead shaker. In some experiments, the resulting supernatants were then analyzed using Aβ antiserum. Immunocomplexes were

obtained with protein A sepharose and analyzed as described in (Weidemann et al., Cell 57, pages 115-126 (1989)).

Antibodies and electrophoresis

For detecting APP, polyclonal rabbit antibodies directed against recombinant Fd-APP770 (antiserum 22734/6 against the amino acid residues 18-687 of APP770 or antiserum 23850/6 against the APP amino acid residues 18-491 (figure 1) were diluted at a concentration of 1:500 for precipitation. The antisera were produced in a laboratory according to standard methods known to the person skilled in the art. A β , p3.5 and β 3 were recognized by the polyclonal antibodies 830 (dilution 1:50; A β , p3.5 and p3 were likewise precipitated) which had been produced against a synthetic peptide corresponding to the A β amino acid residues 1-40 (figure 1). A β and its derivatives were separated by 10-20 % Tris-tricin-polyacrylamide gels and APP using 7 % Tris-glycin-polyacrylamide gels or 7 % Tris-tricin-polyacrylamide gels. For immunoblots cell extracts and extracellular medium were precipitated with 10 % TCA, washed with acetone and dissolved in sample buffer. After the electrophoresis, the gels were further processed as described in (Simons et al., J. Neurosci 16, pages 899-908 (1996)) and quantified with the "Fuji-Bas-PhosphorImager" system. The data were expressed as average values +/- standard deviation and, unless indicated otherwise, they represent the result of at least two separate experiments.

Treatments of active substances and LDH assay

During the labeling period copper chloride or zinc chloride (concentrations: 5 μ M to 200 μ M) were added to the culturing medium. D(-)-penicillamine (PEN; Sigma), bathocuproin-disulfonate (BC; Aldrich) and 1,10-phenanthroline (PEN; Sigma) were added to the medium up to a final concentration of 100 μ M (PEN and BC) or 200 μ M (PEN). The viability of the cells was measured by means of the lactate dehydrogenase (LDH) outflow into the culture (41). The LDH outflow was

measured as enzyme activity (units/liter) after 2 and 4 hours in the medium of 70 % confluent monolayers of CHO cells in "Eagle" medium modified according to Dulbecco (DMEM).

Example 2: APP expression in cells which were transfected with APP695-encoding cDNA

The parental CHO-K1 cell line and the copper-resistant CUR3 cell line were used for studying the role of copper on APP processing with decreasing copper concentrations or increasing copper concentrations (0 - 200 μ M). CUR3 cells were used for investigating the role of intracellular copper on APP processing. As compared to CHO-K1 cells, CUR3 cells show lower intracellular copper concentrations, which is caused by an enhanced outflow of copper as a result of a concentration, increased by a factor of 70, of the "Menkes P-type ATPase copper efflux pump" (intracellular copper pump/intracellular copper export system).

Following the transfection of CHO-K1 and CUR3 cells with cDNA, which encoded APP695 with an N-terminal c-myc epitope (figure 1), APP expression could be detected easily by means of immunoprecipitation with polyclonal c-myc antiserum and subsequent immunoblots with the monoclonal antibody 22C11 (figure 2a,b). The polyclonal c-myc antibody immunoprecipitated c-myc-tagged APP695 with a relative molecular weight of 105 kDa from the cell lysate (cAPP695) and the conditioned medium (sAPP695). In accordance with expectations, c-myc-APP695 could not be detected in either the lysate or the medium of cells which had only been transfected with pcDNA3.

Example 3: Decrease of the A β concentration as a function of increasing copper concentrations

For investigating the regulation of the APP metabolism by copper ions, CHO cells stably transfected with APP695 were labeled for 4 hours with ^{35}S -labeled methionine in the presence of different copper concentrations and following immunoprecipitation with polyclonal antibodies which detect APP (22734/6) or detect A β and p3 (730), the secretions of the APP ectodomain, of A β and p3 were measured. Cell lysates of CUR3 cells showed a band at 105 kDa which corresponds to the immature cAPP695 holoprotein (figure 3a). APP695 derivatives released in conditioned medium were detected as bands of 105 and 97.5 kDa (figure 3b), they probably differing in that the upper band has a higher content of sialic acids. The cell lines showed no reduced viability during the entire experiment.

When CUR3 cells with increasing copper concentrations were incubated, the concentration of the APP holoprotein and of soluble APP also increased significantly. As compared to the basal medium, a maximum of sAPP was obtained with 265 % at 50 μM Cu(II) before a general production of secreted proteins was induced (figure 3c; Table 1). The secretion of p3, the C-terminal counterpart of secretory APP which is produced by cleavage with α -secretase, increased between 20 μM and 50 μM in the medium to 270 % (figure 3d; Table 1). The immunoprecipitation of the radioactively labeled peptide originating from the A β region of APP was made with the rabbit antiserum 730, which recognizes A β (4.5 kDa), p3.5 (3.5 kDa) and p3 (3 kDa) (figure 1). When a copper concentration of 50 μM was exceeded in the medium, this influenced the general protein metabolism, and the percentage of cAPP was markedly higher with 550 % (figure

3c; Table 1). In contrast thereto, the A β concentration was strongly lowered, only 20 % of the basal concentration were present with 50 μ M copper and above 100 μ M copper A β was hardly detectable in CUR3 cells (figure 3d,e). This was also determined for p3.5 (figure 3d), which confirmed the earlier observation that p3.5 is the product of an alternative β -secretase metabolism.

Table 1: Modulation of APP processing in CHO cells*

	SAPP695c	APP695	p3	A β
CUR3 (50 μ M Cu(II))	265	550	270	20
CUR3 (Cu(I)/Cu(II) removal)	77	205	50	100
K1 (10 μ M Cu(II))	475	295	154	20
K2 (Cu(I)/Cu(II) removal)	170	190	171	100

*[%] increase/decrease as compared to standard conditions

Example 4: Stimulation of the A β peptide production by complex formation of copper(I) ions with bathocuproin or the copper(II) ions by penicillamine

The following investigations were made to check whether CAPP, sAPP and subsequent degradation products are modulated by a copper deficiency. In order to study whether copper(II) is necessary for APP expression and processing, copper(II) was removed by means of the copper(II) chelating agent D-penicillamine (PEN) and copper(I) was removed by means of the cell-impermeable copper(I) chelating agent bathocuproindisulfonic acid. It showed that the production of A β and p3.5 was not influenced whereas the concentrations of sAPP and p3 were lowered to 77 % and 50 %, respectively (figure 3d,e; Table 1). This shows that the copper(II)-

induced changes are based on a specific modulation of the APP metabolism by copper.

Example 5: Study of the endogenously expressed KPI-containing APP751/770 isoforms in CHO-K1 cells.

The endogenously expressed isoforms APP751/770 containing KPI (protease inhibitory domain of the Kunitz type, which is introduced into APP751 and APP770 by alternative splicing) were studied in CHO-K1 cells by immunoprecipitation of proteins labeled with [³⁵S]methionine from the cell lysate and conditioned medium with polyclonal APP antiserum 22734 (figure 1; figure 4a,b). The secretion of KPI-AAP corresponded to that of c-myc APP695 (figure 4). Two main bands with a relative molecular weight of 130 kDa and 105 kDa correspond to sAPP751/770 and sAPP695, respectively. The latter could also be precipitated with anti-c-myc antiserum. When CHO-K1 cells were incubated with increasing copper concentrations, the APP levels and p3 levels increased significantly (APP: cAPP to 295 %, sAPP695 to 475 % and sAPP751/770 to 275 % with 10 µM copper and p3 to 154 % with 10 µM copper; figure 4a-e; Table 1). At the same time, the Aβ production was drastically reduced below the detection limit (figure 4d,e). In the presence of copper chelating agents, the sAPP695 secretion was 170 % (figure 5a,b,c), the sAPP751/770 secretion was 190 % (figure 4b,c; Table 1) and the p3 secretion was 171 % (figure 4d,e; Table 1).

Furthermore, the relative level of sAPP694, p3 and Aβ, which were immunoprecipitated from conditioned medium of CHO-K1 cells (a) and CHO-CUR3 cells (b), were quantified. The result is shown in figure 5. The increase in sAPP695 (black squares) reached a maximum at 10 µM Cu(II) (a) in K1 cells and at 50 µM Cu(II) (b) in CUR3 cells; thereafter there was

a decrease. The change of the sAPP level (open triangles) occurred later as compared to the changes with the p3 protein which reached the maximum level with somewhat lower Cu(II) dosages, which is most likely due to a half life longer as compared to sAPP. In contrast thereto, the A β levels (black squares) increased drastically in both cell lines with Cu(II) concentrations below the basal level. The first data point was determined with the basal copper concentration (0.8 μ M Cu(II)).

Example 6: Identification of copper agonists for APP with inhibitory effect on the release of the amyloid A β peptide

The copper-binding peptide of APP and APLP2 (homologous protein of APP which like APP and APLP1 belongs to the APP gene family), APPN262 (an artificially produced C-terminal shortened form of APP which consists of the N-terminal 262 residues of APP) and further artificially produced APP forms which are successively reduced by individual domains from the C terminus), the copper binding site-bearing variants of APP and APLP2 and fragments thereof were contacted with a differing concentration of Zn(II). The employed Zn²⁺ concentrations were 10 μ M, 50 μ M, 100 μ M and 200 μ M. Thereafter, it was studied from which concentration of Zn(II) the release of the A β peptide can be inhibited. The following experiments were carried out for this purpose:

(1) CHO cells which were stably transfected with human APP695 were incubated in MEM medium with the above-mentioned concentrations of Zn(II) (10 to 200 μ M in PBS). CHO cells with copper ions (10 to 50 μ M in PBS) or without any addition were incubated as controls. The production of A β (total), A β 40 and A β 42 was determined qualitatively and quantitatively with polyclonal and monoclonal antibodies.

APP, A β and p3 were detected according to biosynthetic labeling with ^{35}S methionine as followed. The stably transfected CHO cells, which were incubated as mentioned above with the respective substances, were incubated for four hours with 220 μCi ^{35}S methionine as follows. Conditioned medium and cells were harvested and the dissolved proteins were used for the immunoprecipitation. The protein concentrations were determined beforehand using the protein detection kit from BioRad company and the amount of incorporated radioactivity was determined via scintillation counting. The cells were lyzed in extraction buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, 2 % triton X-100, 2 % NP40, 1 mM PMSF, 10 $\mu\text{g/ml}$ aprotinin and 10 μg leupeptin). Cell debris was centrifuged off at 13.000 x g for 10 minutes and the supernatant was adjusted to 25 mM Tris-HCl, pH 8.5, 1 mM PMSF, 10 $\mu\text{g/ml}$ aprotinin, 10 $\mu\text{g/ml}$ leupeptin, 0.5 % triton X-100 and 0.5 % NP 40. The protein solution was diluted at a concentration of 1:2 with 100 mM Tris-HCl, pH 7,5, 300 mM NaCl and 4 mM EDTA. The supernatants were incubated with the above mentioned polyclonal APP and A β antibodies overnight at 4°C, the immunocomplexes formed were isolated with protein A sepharose and analyzed according to the method described in Ida et al., J. Biol. Chem. 271, pp. 22908-22914.

It showed that the A β production could be reduced drastically with a concentration from 50 μM Zn(II). A lowered secretion of APP in CXHO-K1 cells and in CUR3 cells showed with Zn(II) concentrations above 50 μM , in the case of an A β production reduced by 60 % it showed with 50 μM Zn(II) for CUR3 cells (K1: 20 %), by 90 % it showed with 100 μM Zn(II) (K1:305) and by 99 % it showed with 200 μM Zn(II) (K1: 60 %). There was no further decrease of the A β

production above 200 μM Ca(II) , the detection limit having been reached here.

(2) Primary neurons were isolated from transgenic mice which expressed the A β peptide with the human sequence, and their A β production was determined as described in (1).

(3) The above mentioned Zn(II) concentrations in PBS were applied to transgenic mice orally, i.v., i.p., s.c. and i.c. (see (2)) and the A β production was determined in the CNS and in the blood (which was withdrawn from the caudal vein) as outlined above in (1). The serum obtained from the caudal vein of the mice (150 - 200 μl) is filled using PBS buffer up to a volume of 500 μl and incubated with 5 μg monoclonal antibody WO-2 (Ida et al., supra) and 20 μl of a 1:1 suspension of protein G sepharose overnight at 4°C on an overhead shaker. The resulting supernatant is then incubated with polyclonal antibodies (22734/6) against APP and the immunocomplexes are analyzed as described above in (1). The A β immunocomplexes are separated by means of 12 % bis-tricin Novex gels in accordance with the instructions of the manufacturer and the relevant molecular weight range is analyzed after the transfer of the proteins to a nitrocellulose filter (380 mA at 4°C for 40 minutes) with the monoclonal antibody WO-2 using the ECL technique according to Ida et al. The result here was also that a decrease of the A β production could be obtained from a concentration of 50 μM Zn(II).

Claims

1. Copper agonist, characterized in that it binds to the copper binding site of the amyloid precursor protein (APP) and/or reduces or prevents the release of the amyloid A β peptide.
2. The copper agonist according to claim 1, wherein divalent metal ions, oligopeptides, oligonucleotides, oligosaccharides, nucleotide analogs, chemical substance libraries or low molecular natural substances from microorganisms or plants are concerned.
3. Medicaments which contain the copper agonist according to claim 1 or 2, optionally in combination with a pharmaceutically acceptable carrier.
4. Use of the copper agonist according to claim 1 or 2 for the production of a medicament for the prevention or treatment of Alzheimer's disease.
5. A method of identifying a copper agonist which binds to the copper binding site of APP and/or exerts an inhibitory effect on the release of the amyloid A β peptide, which is characterized by the steps of:
 - (a) contacting APP or a fragment thereof carrying the copper binding site with various concentrations of a compound which potentially has the above effect,
 - (b) detecting a decrease of the A β protein.
6. The method according to claim 5, wherein the decrease of the A β protein is detected by means of ELISA or immunoprecipitation from cell culture systems.

7. The method of identifying a copper agonist which binds to the copper binding site of APP and/or exerts an inhibitory effect on the release of the amyloid A β peptide which is characterized by the steps of:
- (a) contacting of APP or a fragment thereof carrying the copper binding site with a dissolved or immobilized substance library or with low molecular substances from microorganisms and/or plants,
 - (b) when a dissolved substance library or liquid low molecular substances are used, immunoprecipitation of the competitive or non-competitive copper binding site/ligand complex from the solution with antibodies specific to APP or the fragment thereof or, when an immobilized substance library is used, release of the ligand from the copper binding site/ligand complex by the addition of copper salts,
 - (c) identification of the ligand, and
 - (d) selection of ligands which after binding to the copper binding site of APP exert an inhibitory effect on the release of the amyloid A β peptide, wherein step (d) can optionally precede step (c).
8. The method according to claim 7, wherein step (d) comprises the incubation of mammalian cells stably transfected with APP695 with the ligand obtained from steps (a) to (c) and the determination of the production of the amyloid A β peptide with polyclonal or monoclonal antibodies.
9. The method according to claim 7, wherein step (d) comprises the administration of the ligand obtained

from steps (a) to (c) to transgenic mammals which express the human amyloid A β peptide, the collection of a sample from the CNS or the blood and the determination of the production of the amyloid A β peptide with polyclonal or monoclonal antibodies.

1/6




Fig. 1




Fig. 2

09/914770

2/6




Fig. 3

09/914770

3/6




Fig. 3 (cont'd)

09/914770




Fig. 4

09/914770

5/6





Fig. 4 (cont'd)

6/6

a



b




Fig. 5

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY
 (Includes Reference to Provisional and PCT International Applications)

Attorney's Docket No.

012627-024

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

COPPER AGONIST THAT BINDS ON THE COPPER BINDING SITE OF APP AND/OR EXERTS AN INHIBITING

EFFECT ON THE RELEASE OF AMYLOID A β PEPTIDE

the specification of which (check only one item below):

☐ is attached hereto.

☐ was filed as United States application

Number _____

on _____

and was amended

on _____ (if applicable).

☐ was filed as PCT international application

Number PCT/DE00/00693

on 1 MARCH 2000

and was amended

on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(e) of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. §119:

COUNTRY (if PCT, indicate "PCT")	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. §119
DE	199 09 357.1	3 MARCH 1999	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

(Application Number)

(Filing Date)

(Application Number)

(Filing Date)

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (CONT'D)
(Includes Reference to Provisional and PCT International Applications)

Attorney's Docket No.

012627-024

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose to the Office all information known to me to be material to the patentability as defined in Title 37, Code of Federal Regulations §1.56, which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:

PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. §120:

U.S. APPLICATIONS		STATUS (check one)		
U.S. APPLICATION NUMBER	U.S. FILING DATE	PATENTED	PENDING	ABANDONED
PCT APPLICATIONS DESIGNATING THE U.S.				
PCT APPLICATION NO.	PCT FILING DATE	U.S. APPLICATION NUMBERS ASSIGNED (if any)		

I hereby appoint the following attorneys and agent(s) to prosecute said application and to transact all business in the Patent and Trademark Office connected therewith and to file, prosecute and to transact all business in connection with international applications directed to said invention:

William L. Mathis	17,337	Eric H. Weisblatt	30,505	Bruce T. Wieder	33,815
Robert S. Swecker	19,885	James W. Peterson	26,057	Todd R. Walters	34,040
Platon N. Mandros	22,124	Teresa Stanek Rea	30,427	Ronni S. Jillions	31,979
Benton S. Duffett, Jr.	22,030	Robert E. Krebs	25,885	Harold R. Brown III	36,341
Norman H. Stepno	22,716	William C. Rowland	30,888	Allen R. Baum	36,086
Ronald L. Grudziecki	24,970	T. Gene Dillahunt	25,423	Brian P. O'Shaughnessy	32,747
Frederick G. Michaud, Jr.	26,003	Patrick C. Keane	32,858	Kenneth B. Leffler	36,075
Alan E. Kopecki	25,813	B. Jefferson Boggs, Jr.	32,344	Fred W. Hathaway	32,236
Regis E. Slutter	26,999	William H. Benz	25,952	Wendi L. Weinstein	34,456
Samuel C. Miller, III	27,360	Peter K. Skiff	31,917	Mary Ann Dillahunt	34,576
Robert G. Mukai	28,531	Richard J. McGrath	29,195		
George A. Hovanec, Jr.	28,223	Matthew L. Schneider	32,814		
James A. LaBarre	28,632	Michael G. Savage	32,596		
E. Joseph Gess	28,510	Gerald F. Swiss	30,113		
R. Danny Huntington	27,903	Charles F. Wieland III	33,096		



21839

and: _____

Address all correspondence to:



21839

Teresa Stanek Rea
BURNS, DOANE, SWECKER & MATHIS, L.L.P.
P.O. Box 1404
Alexandria, Virginia 22313-1404

Address all telephone calls to: 7Teresa Stanek Rea at (703) 836-6620.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (CONT'D)
(Includes Reference to Provisional and PCT International Applications)

Attorney's Docket No.

012627-024

FULL NAME OF SOLE OR FIRST INVENTOR <u>Konrad BEYREUTHER</u>		SIGNATURE <i>K. Beyreuther</i>	DATE <u>26.10.01</u>
RESIDENCE <u>Ludolf-Krehl-Strasse 25, Heidelberg</u> DEX		CITIZENSHIP Germany	
POST OFFICE ADDRESS <u>Ludolf-Krehl-Strasse 25, Heidelberg 69120 GERMANY</u>			
FULL NAME OF SECOND JOINT INVENTOR, IF ANY <u>Gerd MULTHAUP</u>		SIGNATURE <i>G. Multhaupt</i>	DATE <u>26.10.2001</u>
RESIDENCE <u>Fritz von Briesen Strasse 16, Dilsberg</u> DEX		CITIZENSHIP Germany	
POST OFFICE ADDRESS <u>Fritz von Briesen Strasse 16, Dilsberg 69151 GERMANY</u>			
FULL NAME OF THIRD JOINT INVENTOR, IF ANY <u>Colin L. MASTERS</u>		SIGNATURE <i>C. Masters</i>	DATE <u>5/11/2001</u>
RESIDENCE <u>171 Gold Street, Clifton Hill, Victoria / AUSTRALIA</u> AX		CITIZENSHIP AUSTRALIAN	
POST OFFICE ADDRESS <u>171 Gold Street, Clifton Hill, Victoria 3068 / AUSTRALIA</u>			
FULL NAME OF FOURTH JOINT INVENTOR, IF ANY		SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF FIFTH JOINT INVENTOR, IF ANY		SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF SIXTH JOINT INVENTOR, IF ANY		SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF SEVENTH JOINT INVENTOR, IF ANY		SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF EIGHTH JOINT INVENTOR, IF ANY		SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (CONT'D) (Includes Reference to Provisional and PCT International Applications)	Attorney's Docket No. 012627-024
---	-------------------------------------

FULL NAME OF NINTH JOINT INVENTOR, IF ANY	SIGNATURE	DATE
RESIDENCE	CITIZENSHIP	
POST OFFICE ADDRESS		
FULL NAME OF TENTH JOINT INVENTOR, IF ANY	SIGNATURE	DATE
RESIDENCE	CITIZENSHIP	
POST OFFICE ADDRESS		

COMBINED DECLARATION FOR PATENT APPLICATION & POWER OF ATTORNEY
(Includes Reference to Provisional and PCT International Applications)
Supplemental Sheet

Attorney's Docket No.

012627-024

Full Name of Additional Joint Inventor, If Any	
Signature	
Date	
Residence (City, State, Country)	
Citizenship	
Post Office Address	
Full Name of Additional Joint Inventor, If Any	
Signature	
Date	
Residence (City, State, Country)	
Citizenship	
Post Office Address	
Full Name of Additional Joint Inventor, If Any	
Signature	
Date	
Residence (City, State, Country)	
Citizenship	
Post Office Address	
Full Name of Additional Joint Inventor, If Any	
Signature	
Date	
Residence (City, State, Country)	
Citizenship	
Post Office Address	